The Pulmonary-Allergy Drugs Advisory Committee (PADAC) of the US Food and Drug Administration (FDA) has recommended the approval of GlaxoSmithKline (GSK) and Theravance's umeclidinium/vilanterol as a treatment for chronic obstructive ...
Tags: Health, Medicine, Investigational Copd Drug
Swiss drugmaker Novartis has announced that once-daily dual bronchodilator, Ultibro Breezhaler (QVA149), has achieved positive CHMP opinion for the treatment of chronic obstructive pulmonary disease (COPD). Ultibro Breezhaler was ...
AstraZeneca has agreed to purchase California-based respiratory medication developer, Pearl Therapeutics, in a deal with a total potential cost of up to $1.15bn. As per the definitive agreement signed between both the parties, AstraZeneca ...
Tags: AstraZeneca, Pearl Therapeutics
GlaxoSmithKline (GSK) has submitted a new drug application (NDA) to the US FDA for umeclidinium bromide (UMEC) monotherapy 62.5mcg to treat chronic obstructive pulmonary disease (COPD). The investigational once-daily UMEC, administered ...
Tags: GlaxoSmithKline, FDA Approval, chronic obstructive pulmonary disease
GSK and Theravance have announced the submission of a regulatory application for Anoro Ellipta (UMEC/VI) (62.5/25mcg and 125/25mcg doses) in Japan. UMEC/VI combines a long-acting muscarinic antagonist (LAMA) GSK573719 or umeclidinium ...
GlaxoSmithKline and Theravance have announced the MAA submission for Anoro in Europe for patients with chronic obstructive pulmonary disease (COPD). The COPD therapy, administered using the ELLIPTA inhaler, is a combination of GSK573719 ...
Tags: GlaxoSmithKline, COPD therapy, chronic obstructive pulmonary disease
GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for the investigational once-daily LAMA/LABA combination medicine, umeclidinium bromide (UMEC/VI), to treat chronic obstructive pulmonary disease (COPD) ...
Tags: GlaxoSmithKline, regulatory application, Medicine, FDA
Theravance has commenced Phase 2b study desined to evaluate varying doses of TD-4208 in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Theravance leveraged its multivalent approach of drug design to ...
Tags: drug, long-acting medicines, long-acting muscarinic antagonist
Sosei Group Corporation,Japan, has received a positive opinion for its Seebri Breezhaler (glycopyrronium bromide/NVA237),a type of bronchodilator, from European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). ...
Tags: Seebri Breezhaler, bronchodilator, CHMP, Positive Chmp Opinion